Meeting
2017 ASCO Annual Meeting
Comparison of two different neoadjuvant chemoradiatiotherapy regimens for locally advanced rectal cancer: Results of a phase II, multicenter, randomized trial.
Authors
Ji Zhu
Fudan University Shanghai Cancer Center, Shanghai, China
Ji Zhu , Yun Guan , Senxiang Yan , Ye Xu , Xinxiang Li , Sanjun Cai , Zhen Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT01064999
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3614)
DOI
10.1200/JCO.2017.35.15_suppl.3614
Abstract #
3614
Poster Bd #
237
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Results of the phase II TRUST trial of induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC).
First Author: Gianluca Masi
Poster
2014 Gastrointestinal Cancers Symposium
Chemoradiation (CRT) followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant CRT and surgery for locally advanced rectal cancer: Results of the Spanish GCR-3 randomized phase II trial after a median follow-up of 5 years.
First Author: Carlos Fernandez-Martos
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2023 ASCO Annual Meeting
Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).
First Author: Salvatore Siena